The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer

被引：0
|
作者：
Boer R.
机构：
来源：
Breast Cancer Research | / 1卷 / 1期
关键词：
HER-2; Metastatic breast cancer; Monoclonal antibody;
D O I：
10.1186/bcr-1999-66610
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
相关论文
共 50 条
  • [21] Brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS)
    Gori, S.
    Rimondini, S.
    De Angelis, V.
    Sidoni, A.
    Mosconi, A. M.
    Aristei, C.
    Perrucci, E.
    Basurto, C.
    Franceschi, E.
    Scopece, L.
    Degli Esposti, R.
    Colozza, M.
    Crino, L.
    ANNALS OF ONCOLOGY, 2005, 16 : 10 - 11
  • [22] Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Hanson, Sarah
    Greco, F. Anthony
    Spigel, David R.
    Barton, John
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (03) : 178 - 183
  • [23] Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer
    Zucchini, G.
    Bernardi, A.
    Martoni, A.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 264 - 265
  • [24] Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
    Niikura, Naoki
    Liu, Jun
    Hayashi, Naoki
    Mittendorf, Elizabeth A.
    Gong, Yun
    Palla, Shana L.
    Tokuda, Yutaka
    Gonzalez-Angulo, Ana M.
    Hortobagyi, Gabriel N.
    Ueno, Naoto T.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : 593 - 599
  • [25] Herceptin (R) is active as a single agent in women with metastatic breast cancer overexpressing HER2
    Cobleigh, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S316 - S316
  • [26] Trastuzumab (Herceptin®):: Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
    Ditsch, Nina
    Rueckert, Sandra
    Kuemper, Carolin
    Lenhard, Miriam
    Kahlert, Steffen
    Bauerfeind, Ingo
    Friese, Klaus
    Untch, Michael
    BREAST CARE, 2006, 1 (02) : 78 - 84
  • [27] Activity of fulvestrant in HER2-overexpressing advanced breast cancer
    Robertson, J. F. R.
    Steger, G. G.
    Neven, P.
    Barni, S.
    Gieseking, F.
    Nole, F.
    Pritchard, K. I.
    O'Malley, F. P.
    Simon, S. D.
    Kaufman, B.
    Petruzelka, L.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1246 - 1253
  • [28] Target Therapy in HER2-Overexpressing Breast Cancer Patients
    Amodio, Rosalba
    Zarcone, Maurizio
    Cusimano, Rosanna
    Campisi, Ildegarda
    Dolcemascolo, Cecilia
    Traina, Adele
    Agostara, Biagio
    Romano, Nino
    OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2011, 15 (06) : 363 - 367
  • [29] A phase II study of humanized anti-HER2 monoclonal antibody (rhuMAB HER2) and weekly chemotherapy in women with metastatic progressive breast cancer
    Colozz, M
    Gori, S
    Mosconi, AM
    Di Stefano, A
    Mazzoni, F
    Maestri, A
    Cherubini, R
    Crino, L
    Tonato, M
    ANNALS OF ONCOLOGY, 2000, 11 : 39 - 39
  • [30] THE ROLE OF HER3 EXPRESSION AND PTEN LOSS IN PATIENTS WITH HER2-OVEREXPRESSING METASTATIC BREAST CANCER (MBC)
    Park, Y. H.
    Jung, H. A.
    Choi, Y. L.
    Do, I. -G.
    Ahn, J. -S.
    Im, Y. -H.
    ANNALS OF ONCOLOGY, 2013, 24
12345